Evidence Hub

The role of Kynurenine-Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) axis in migraine pathophysiology and therapy

Körtési T, Ajkay-Donáth L, Vágvölgyi-Sümegi E, Tapody Z, Varga N, Kis-György R, Szok D, Nagy-Grócz G et al.

Ideggyogyaszati szemle, 2026

Abstract

Migraine is one of the most common types of primary headaches, and its pathomecha nism is not yet fully understood. Our know ledge of its pathophysiology has previously focused primarily on the serotonin system; however, in recent years, increa sing attention has been given to tryptophan metabolism, particularly the Kynurenine pathway (KP). The KP, which is involved in the regulation of glutamatergic neurotransmission, is responsible for the synthesis of several neuroprotective and neurotoxic metabolites. Kynurenic acid (KYNA) is endogenous glutamate NMDA receptor antagonist in the body. Experimental data indicate that KYNA plays an important role in the pathophysiology of migraine attacks. Preclinical studies support that KYNA and its synthetic analogs are able to inhibit the pathological processes occur ring during migraine. Our previous clinical studies have confirmed that in patients with migraine, the balance maintained by neuroprotective and neurotoxic KP metabolites is disrupted, affecting both the protective and the toxic side. It is important to note, however, that various molecules of KP metabolism can exert both positive and negative effects depending on their concentration at multiple sites of the body, and therefore there is no international consensus regarding the spectrum of protective and toxic molecules. Recently, "migraine associated" neuropeptides have emerged as another promising target for migraine therapy. Calcitonin gene related peptide (CGRP) and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free